The model combines estimates of skeletal muscle with routinely collected clinical data and unstructured notes and predicts the individual likelihood of cachexia.

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.

The UK-based company will evaluate BFB-101 in up to five children with hereditary spastic paraplegia type 47 in a Phase I/II trial.

In the study, patients with advanced solid tumors must be HLA-A*02:01 positive and harbor a p53 R175H mutation.